In rheumatology, which type of interstitial lung disease (ILD) is most commonly seen in rheumatoid arthritis (RA) and how does it differ from ILD patterns in other rheumatic diseases?

Interstitial Lung Disease Patterns in Rheumatoid Arthritis and Other Rheumatic Diseases

Rheumatoid Arthritis-Associated ILD

In rheumatoid arthritis, the usual interstitial pneumonia (UIP) pattern is the most common radiologic subtype of ILD, occurring more frequently than in other connective tissue diseases and carrying a worse prognosis than non-UIP patterns 1, 2, 3.

Key Characteristics of RA-ILD:

Histopathologic Patterns:

• UIP is the predominant pattern in RA-ILD, distinguishing it from most other connective tissue diseases where nonspecific interstitial pneumonia (NSIP) typically predominates 1, 2, 4
• NSIP pattern occurs less frequently but is associated with better outcomes 4
• Organizing pneumonia pattern is occasionally seen 4

Clinical Features:

• Clinically significant RA-ILD affects approximately 10-15% of RA patients, with additional subclinical disease detected on imaging 1, 5
• The UIP pattern shows peripheral and basal predominant reticulation, honeycombing with or without traction bronchiectasis 6
• High-resolution CT (HRCT) demonstrates 96-100% specificity in predicting histological UIP pattern 1

Risk Factors for RA-ILD:

• Male sex (male:female ratio approximately 1:1 for RA-ILD overall, but UIP pattern shows strong male predominance 8:2) 3, 4
• Older age (median age at diagnosis 64 years) 3
• Current or former smoking history (particularly strong association in males) 3, 4
• Anti-CCP antibodies (strongest single predictor) 3
• Rheumatoid factor positivity 3

Prognostic Implications:

• RA-ILD with UIP pattern has significantly worse survival compared to non-UIP patterns 1, 2, 4
• Median survival for RA-ILD is poor at 2.6-3.0 years 1
• Extensive disease on HRCT is associated with increased all-cause mortality 3
• Five-year mortality data shows deaths predominantly in UIP pattern patients versus zero deaths in NSIP pattern patients in one cohort 4

ILD Patterns in Other Rheumatic Diseases

Systemic Sclerosis (SSc):

• NSIP is the predominant pattern, contrasting with RA 7, 8
• Requires more frequent monitoring (every 3-6 months in first year) 7
• Glucocorticoids are strongly recommended AGAINST as first-line treatment for SSc-ILD, unlike other systemic autoimmune rheumatic diseases 8

Idiopathic Inflammatory Myopathies (IIM):

• NSIP pattern more common than UIP 7
• Anti-MDA-5 and anti-synthetase antibodies indicate high risk for rapidly progressive ILD 7
• JAK inhibitors and calcineurin inhibitors are conditionally recommended as first-line options specifically for IIM-ILD 8

Sjögren's Disease and Mixed Connective Tissue Disease:

• Variable patterns but generally less fibrotic than RA-UIP 7, 8
• NSIP more common than UIP

Screening and Monitoring Recommendations

Per 2023 ACR/CHEST Guidelines 7:

Screen with both pulmonary function testing (spirometry, lung volumes, DLCO) AND HRCT chest if:

• Signs or symptoms of ILD present
• High-risk autoantibodies detected (anti-Scl-70, anti-MDA-5, anti-synthetase)
• Presence of ILD risk factors in RA: male sex, older age, smoking, elevated RA-related autoantibodies, obesity, high RA disease activity 5

Monitoring frequency once ILD diagnosed:

• RA-ILD: Every 3-12 months in first year with PFTs, then less frequently once stable 7
• Ambulatory desaturation testing every 3-12 months 7
• HRCT chest as needed for progression assessment 7

Tests recommended AGAINST for routine screening:

• Chest radiography (inadequate sensitivity)
• Surgical lung biopsy (strong recommendation against for routine use) 7

Treatment Implications

For RA-ILD specifically 8:

• Glucocorticoids are conditionally recommended as first-line treatment (unlike SSc-ILD where they are contraindicated)
• Mycophenolate, azathioprine, rituximab, and cyclophosphamide are first-line options
• Nintedanib: No consensus reached for RA-ILD (contrasts with conditional recommendation FOR SSc-ILD and AGAINST for other SARDs)
• Methotrexate, TNF inhibitors, and abatacept are conditionally recommended AGAINST

Critical Pitfalls:

1. Do not assume NSIP predominance in RA-ILD as you would in other connective tissue diseases—UIP is more common and requires different prognostic counseling
2. Male smokers with RA warrant heightened ILD surveillance given their substantially elevated risk
3. Anti-CCP antibody levels should trigger ILD screening consideration, not just guide arthritis treatment
4. HRCT is essential for pattern determination—pulmonary function tests alone are insufficient for subtyping
5. UIP pattern in RA-ILD predicts poor prognosis similar to idiopathic pulmonary fibrosis, requiring aggressive monitoring and early treatment consideration
6. Do not use glucocorticoids as first-line therapy in SSc-ILD despite their conditional recommendation in other SARD-ILD including RA-ILD

The distinction between UIP and non-UIP patterns in RA-ILD has profound therapeutic and prognostic implications that should guide multidisciplinary management between rheumatology and pulmonology 7, 1.